HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Negative HER2/neu amplification using immunohistochemistry and chromogenic in situ hybridization techniques in skin melanoma cases.

AbstractBACKGROUND:
This study was performed to evaluate the amplification of HER-2/neu in patients with melanoma.
MATERIALS AND METHODS:
Amplification of HER-2/neu was evaluated in a group of patients with melanoma, referred to two referral centers in Tehran, using immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) techniques.
RESULTS:
Forty patients with mean age 57.9±19.5 years were enrolled in this study. The most frequent type of melanoma was acral, while lower limbs were the most frequent sites. The amplification of HER2/ neu was negative in 97.5% of patients with IHC and in 100% of patients with CISH technique. Only one case (2.5%) shows weak positive staining (+2) in IHC method. Fifty five percent of melanoma was ulcerative, and the most common stages of tumors were stages 4b and 3b. More than 47% of cases were in Clark level III, while the mean of Breslow thickness was 3.56±2.87 mm. The stage of the case that showed weakly positive staining (2+) in IHC was 4b.
CONCLUSIONS:
The amplification of HER2/neu biomarker was negative in patients with melanoma, using both CISH and IHC techniques.
AuthorsNasrin Shayanfar, Leila Bahari, Zahra Safaie-Naraghi, Kambiz Kamyab, Elmira Gheytanchi, Nima Rezaei
JournalAsian Pacific journal of cancer prevention : APJCP (Asian Pac J Cancer Prev) Vol. 16 Issue 2 Pg. 421-5 ( 2015) ISSN: 2476-762X [Electronic] Thailand
PMID25684465 (Publication Type: Journal Article)
Chemical References
  • Biomarkers, Tumor
  • ERBB2 protein, human
  • Receptor, ErbB-2
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor (genetics, metabolism)
  • Child
  • Cross-Sectional Studies
  • Female
  • Follow-Up Studies
  • Gene Amplification
  • Humans
  • Immunoenzyme Techniques
  • In Situ Hybridization
  • Male
  • Melanoma (genetics, metabolism, pathology)
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Receptor, ErbB-2 (genetics, metabolism)
  • Skin Neoplasms (genetics, metabolism, pathology)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: